{"id":"W2945244577","doi":"10.1016/j.clcc.2019.05.003","title":"Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)","year":2019,"lang":"en","type":"article","venue":"Clinical Colorectal Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; McGill University; University of Toronto; Jewish General Hospital","funders":"Cilag; Genentech; Servier; Five Prime Therapeutics; Sirtex Medical; Terumo; Takeda Pharmaceutical Company; Merck KGaA; Gilead Sciences; Roche; Novartis; Meso Scale Diagnostics; Sanofi; Merck; British Microcirculation Society; Amgen; Pfizer; Celgene; Bayer; Shire; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Aflibercept; FOLFIRI; Medicine; Colorectal cancer; Oncology; Quality of life (healthcare); Internal medicine; Cancer; Bevacizumab; Irinotecan; Chemotherapy; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001697151,0.0002350085,0.0004574782,0.0001727434,0.0001471914,0.0002882528,0.0001586426,0.0001997872,0.0008443781],"category_scores_gemma":[0.00149087,0.00006542894,0.0007437018,0.0002498499,0.0002051852,0.0002092752,0.0001766587,0.000797721,0.000123237],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005724042,"about_ca_system_score_gemma":0.0006302455,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001301439,"about_ca_topic_score_gemma":0.002191895,"domain_scores_codex":[0.999678,0.0001444737,0.00002383382,0.00003333612,0.00007524937,0.00004510724],"domain_scores_gemma":[0.9990446,0.0002502059,0.0003981916,0.00005358879,0.00008575469,0.000167671],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1649114,0.02071197,0.2786997,0.001046749,0.002575886,0.0005088503,0.0006208642,0.002784157,0.0238993,0.0001985141,0.004333477,0.4997091],"study_design_scores_gemma":[0.0396459,0.2969311,0.6439814,0.0001033353,0.001480904,0.00145897,0.0001843969,0.002184085,0.006682292,0.0001732192,0.007142186,0.00003229826],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960681,0.002131183,0.0002189988,0.0002775606,0.00001580287,0.0001481238,0.0003220625,0.00001133593,0.0008067208],"genre_scores_gemma":[0.9976622,0.0008860016,0.0002923424,0.0002157601,0.00003558536,0.00004227889,0.000585958,0.000002779684,0.0002771127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001697151,"threshold_uncertainty_score":0.008975506,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1939368141335871,"score_gpt":0.4612977363386604,"score_spread":0.2673609222050733,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}